Shares of Skyline Medical Inc (NASDAQ:SKLN) ended Monday session in green amid volatile trading. The shares closed up +0.001 points or 0.51% at $0.176 with 4.13 million shares getting traded. Post opening the session at $0.18, the shares hit an intraday low of $0.17 and an intraday high of $0.18 and the price vacillated in this range throughout the day. The company has a market cap of $14.32 million and the numbers of outstanding shares have been calculated to be 81.80 million shares.
Skyline Medical Inc (SKLN) on Sept. 26, 2016 announced that Dr. Carl Schwartz, Interim Chief Executive Officer of Skyline Medical; Bob Beringer, Chief Executive Officer of Electronic On-Ramp; and Richard Gabriel, Co-founder and Chief Operating Officer of GLG Pharma, LLC. will be interviewed on WPSL’s “MONEYINFO by PRINCETON RESEARCH with MIKE KING and CHARLES MOSKOWITZ” show on Tuesday, September 27th. The show will begin at 10:05 a.m. Eastern time and management’s interview will begin at 10:20 a.m.
Management is expected to discuss recent news that Skyline Medical has signed a partnership agreement with GLG, which intends to develop rapid diagnostic tests that utilize fluid and tissue collected by the STREAMWAY System during procedures, and its expected joint venture with Electronic On-Ramp to supply STREAMWAY to U.S. government mobile operating rooms, including disaster relief sites.
To listen to the interview live, investors may visit WPSL’s website at www.wpsl.com. A replay will be available on the investor relations section of Skyline Medical’s website at www.skylinemedical.com.
Shares of Celgene Corporation (NASDAQ:CELG) ended Monday session in red amid volatile trading. The shares closed down -3.12 points or -2.85% at $106.31 with 4.13 million shares getting traded. Post opening the session at $109.00, the shares hit an intraday low of $105.97 and an intraday high of $109.42 and the price vacillated in this range throughout the day. The company has a market cap of $81.55 billion and the numbers of outstanding shares have been calculated to be 775.11 million shares.
Celgene Corporation (CELG) on September 12, 2016 announced interim topline data from a randomized, double-blind, multicenter, exploratory phase 1b study evaluating the effects of oral GED-0301 (mongersen) on both endoscopic and clinical outcomes in patients with active Crohn’s disease.
The trial, CD-001, is an ongoing study evaluating three different treatment regimens of GED-0301 in a 12-week treatment phase, followed by an observation phase up to 52 weeks (off treatment). The primary objective of the study is to explore the effect of GED-0301 on endoscopic outcomes. The trial enrolled a total of 63 patients across multiple countries.
The study was designed to further enhance the understanding of GED-0301 activity in a difficult-to-treat, moderate-to-severe patient population. This population was more diverse than prior GED-0301 studies and included patients with endoscopically confirmed mucosal damage at entry and those who had previous surgeries. The study also included both biologic exposed and biologic naïve patients as well as patients with a diagnosis of Ileitis, Ileocolitis or colitis.
Topline data from CD-001 show that in a proportion of patients treated with oral GED-0301 there was endoscopic improvement (defined as a 25 percent improvement from baseline) and clinical response and remission across all treatment groups at week 12. Findings to date reveal no new safety signals and tolerability is consistent with earlier studies.
“Given the high unmet need in Crohn’s disease, we are pleased that oral GED-0301 showed both endoscopic improvements and clinically meaningful responses and remission at an early timepoint in this study,” said Scott Smith, President of Celgene Inflammation and Immunology. “These data are particularly encouraging for several reasons, including the difficult-to-treat patient population evaluated in the trial.”